Key result
Central venous catheters linked to ~456% greater VTE recurrence risk in cancer patients.
Why the study?
Catheter-related thrombosis occurs in approximately 2-6% of cancer patients, prompting evaluation of the rate of venous thromboembolism recurrence.
Cohort (n=200)
No
Effect estimate: HR 5.56 (95% CI 1.96-15.75)
In cancer patients with catheter-related upper extremity DVT, VTE recurrence is high (25.5%) despite anticoagulation, driven by previous VTE and continued CVC presence.
Signals elevated recurrence risk in cancer patients with prior VTE or CVC; extends observational data but leaves practice change open.
Long-term indwelling central venous catheters (CVC) are frequently used to secure vascular access to deliver injectable treatment. Catheter-related thrombosis (CRT) occurs in approximately 2-6% of cancer patients. We conducted a single-center retrospective study to assess the rate of venous thromboembolism (VTE) recurrence in cancer patients; 200 patients were included. Mean age was 56 ± 15.15 years, median follow-up duration was 16.5 [range: 10-36] months. The incidence of recurrence was estimated using Gray's method for competing risk with death as the competing event of VTE. Recurrent VTE occurred in 25.5% of patients with a median occurrence time of 6.5 [range: 5-11.25] months. In case of recurrence, 94.6% of patients were treated for cancer and 80.4% of them received anticoagulants; 4 major bleeds and 17 non-major bleeds occurred during follow-up. In multivariate analysis, previous VTE (Hazard Ratio (HR) 2.48 (95% CI 1.42-4.32) and presence of CVC (HR 5.56 (95% CI 1.96-15.75) were significant recurrence risk factors. After a first episode of CRT, 25.5% of patients experienced VTE recurrence as UEDVT in 30 cases (55.5%), PE in 17 cases (31.5%), and DVT in 7 cases (13%), mostly during anticoagulation therapy. Anticoagulation therapy does not avoid CRT in case of cancer and must be balanced with hemorrhagic risk.
No takes yet. Share an insight, caveat, or question.
Hakem et al. (2023) conducted a cohort in Catheter-related upper extremity deep venous thrombosis in cancer patients (n=200). Presence of central venous catheter (CVC) and previous VTE was evaluated on Venous thromboembolism (VTE) recurrence (HR 5.56, 95% CI 1.96-15.75). Previous VTE (HR 2.48; 95% CI 1.42-4.32) and the presence of a central venous catheter (HR 5.56; 95% CI 1.96-15.75) were significant risk factors for VTE recurrence in cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: